Research & Literature

Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.

Press R, Hiew FL, Rajabally YA

Acta neurologica Scandinavica 2016; (133(4)):228-38 doi:10.1111/ane.12519.

Outcome of Guillain-Barre syndrome patients with respiratory paralysis.

Kalita J, Ranjan A, Misra UK

QJM : monthly journal of the Association of Physicians 2016; (109(5)):319-23 doi:10.1093/qjmed/hcv190.

[Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy].

Kanbayashi T, Sonoo M

Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(11)):1388-96 doi:10.11477/mf.1416200311.

Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Devaux JJ, Miura Y, Fukami Y, et al.

Neurology 2016; (86(9)):800-7 doi:10.1212/WNL.0000000000002418.

Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Merkies IS, Kieseier BC

European neurology 2016; (75(3-4)):199-206 doi:10.1159/000445347.

Rituximab in autoimmune diseases.

Randall KL

Australian prescriber 2016; (39(4)):131-134 doi:10.18773/austprescr.2016.053.

Swallowing and swallowing-breathing interaction as predictors of intubation in Guillain-Barré syndrome.

Ogna A, Prigent H, Lejaille M, et al.

Brain and behavior 2017; (7(2)):e00611 doi:10.1002/brb3.611.

Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis.

Allen JA, Ney J, Lewis RA

Muscle & nerve 2018; (57(4)):542-549 doi:10.1002/mus.25997.

History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Dyck PJB, Tracy JA

Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.

Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review.

Abbas A, Rajabally YA

Current drug safety 2019; (14(1)):3-13 doi:10.2174/1574886313666181017121139.

Infusion-related reactions to rituximab: frequency, mechanisms and predictors.

Paul F, Cartron G

Expert review of clinical immunology 2019; (15(4)):383-389 doi:10.1080/1744666X.2019.1562905.

Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis.

Breiner A, Bourque PR, Allen JA

Muscle & nerve 2019; (60(2)):180-183 doi:10.1002/mus.26488.

Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.

Lucke IM, Wieske L, van der Kooi AJ, et al.

Journal of the peripheral nervous system : JPNS 2019; (24(2)):174-179 doi:10.1111/jns.12325.

Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective.

Watkins JM, Dimachkie MM, Riley P, Murphy E

The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 2019; (51(4)):198-203 doi:10.1097/JNN.0000000000000451.

Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? - A Cochrane Overview summary with commentary.

Oaklander AL, Gimigliano F

NeuroRehabilitation 2019; (44(4)):609-612 doi:10.3233/NRE-189007.

Nerve ultrasound can identify treatment-responsive chronic neuropathies without electrodiagnostic features of demyelination.

Goedee HS, Herraets IJT, Visser LH, et al.

Muscle & nerve 2019; (60(4)):415-419 doi:10.1002/mus.26629.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, et al.

Neurology(R) neuroimmunology & neuroinflammation 2019; (6(5)):e590 doi:10.1212/NXI.0000000000000590.

Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy.

Bunschoten C, Blomkwist-Markens PH, Horemans A, et al.

Journal of the peripheral nervous system : JPNS 2019; (24(3)):253-259 doi:10.1111/jns.12344.

Comparison of Lewis-Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre.

Fargeot G, Maisonobe T, Psimaras D, et al.

European journal of neurology 2020; (27(3)):522-528 doi:10.1111/ene.14101.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Shije J, Brannagan TH

Seminars in neurology 2019; (39(5)):596-607 doi:10.1055/s-0039-1693008.

Therapeutic Plasma Exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Pham HP, Schwartz J

Presse medicale (Paris, France : 1983) 2019; (48(11 Pt 2)):338-346 doi:10.1016/j.lpm.2019.03.016.

Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.

Cortese A, Lombardi R, Briani C, et al.

Neurology(R) neuroimmunology & neuroinflammation 2020; (7(1)) doi:10.1212/NXI.0000000000000639.

Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy.

Su X, Kong X, Lu Z, et al.

Korean journal of radiology 2020; (21(4)):483-493 doi:10.3348/kjr.2019.0739.

Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment.

Pegat A, Boisseau W, Maisonobe T, et al.

Journal of the peripheral nervous system : JPNS 2020; (25(2)):162-170 doi:10.1111/jns.12380.

Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy.

Koike H, Katsuno M

Neurology and therapy 2020; (9(2)):213-227 doi:10.1007/s40120-020-00190-8.

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

Delmont E, Brodovitch A, Kouton L, et al.

Journal of neurology 2020; (267(12)):3664-3672 doi:10.1007/s00415-020-10041-z.

Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy.

Tracy JA, Taylor BV, Kiernan M, et al.

Journal of clinical neuromuscular disease 2020; (22(1)):1-10 doi:10.1097/CND.0000000000000279.

What Is in the Literature.

Bromberg MB

Journal of clinical neuromuscular disease 2020; (22(1)):35-41 doi:10.1097/CND.0000000000000298.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Its Variants.

Gwathmey K

Continuum (Minneapolis, Minn.) 2020; (26(5)):1205-1223 doi:10.1212/CON.0000000000000907.

Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy.

Sotgiu S, Onida I, Magli G, et al.

Neuropediatrics 2021; (52(1)):56-61 doi:10.1055/s-0040-1715626.

Mechanical ventilation in Guillain-Barré syndrome.

Shang P, Zhu M, Baker M, et al.

Expert review of clinical immunology 2020; (16(11)):1053-1064 doi:10.1080/1744666X.2021.1840355.

Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.

Allen JA, Pasnoor M, Dimachkie MM, et al.

Neurology 2021; (96(14)):e1876-e1886 doi:10.1212/WNL.0000000000011703.

CIDP mimics: a case series.

Moshe-Lilie O, Ensrud E, Ragole T, et al.

BMC neurology 2021; (21(1)):94 doi:10.1186/s12883-021-02118-7.

Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features.

Benoit C, Svahn J, Debs R, et al.

Journal of the peripheral nervous system : JPNS 2021; (26(2)):193-201 doi:10.1111/jns.12438.

Treatment Approaches for Atypical CIDP.

Menon D, Katzberg HD, Bril V

Frontiers in neurology 2021; (12()):653734 doi:10.3389/fneur.2021.653734.

Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy.

Rajabally YA, Afzal S, Ghasemi M

Muscle & nerve 2021; (64(1)):37-42 doi:10.1002/mus.27250.

Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies.

Ruiz M, Puthenparampil M, Campagnolo M, et al.

Journal of neurology, neurosurgery, and psychiatry 2021; (92(9)):969-974 doi:10.1136/jnnp-2020-325868.

Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.

Vu T, Anthony N, Alsina R, et al.

Muscle & nerve 2021; (64(3)):351-357 doi:10.1002/mus.27345.

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

Bus SRM, Broers MC, Lucke IM, et al.

Journal of neurology 2022; (269(2)):945-955 doi:10.1007/s00415-021-10677-5.

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.

Goyal NA, Karam C, Sheikh KA, Dimachkie MM

Muscle & nerve 2021; (64(3)):243-254 doi:10.1002/mus.27356.

European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

Paraproteinemia and neuropathy.

Koike H, Katsuno M

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(11)):4489-4501 doi:10.1007/s10072-021-05583-7.

An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy.

Kapoor M, Compton L, Rossor A, et al.

Journal of the peripheral nervous system : JPNS 2021; (26(4)):461-468 doi:10.1111/jns.12470.

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.

van Veen R, Wieske L, Lucke I, et al.

Journal of the peripheral nervous system : JPNS 2022; (27(2)):144-158 doi:10.1111/jns.12497.

Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.

Rajabally YA, Ouaja R, Kasiborski F, et al.

Muscle & nerve 2022; (66(5)):562-567 doi:10.1002/mus.27713.

Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy.

Al-Zuhairy A, Jakobsen J, Moldovan M, Krarup C

Muscle & nerve 2022; (66(6)):715-722 doi:10.1002/mus.27722.

Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

Lewis RA, van Doorn PA, Sommer C

Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

Chronic inflammatory neuropathies and their impact on activities and participation.

Wonink HA, Kruithof WJ, Goedee HS, Beelen A

European journal of neurology 2023; (30(7)):1928-1936 doi:10.1111/ene.15815.

Immune-Mediated Neuropathies: Pathophysiology and Management.

Shastri A, Al Aiyan A, Kishore U, Farrugia ME

International journal of molecular sciences 2023; (24(8)) doi:10.3390/ijms24087288.

Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.

Bril V, Hadden RDM, Brannagan TH, et al.

Journal of the peripheral nervous system : JPNS 2023; (28(3)):436-449 doi:10.1111/jns.12573.

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy.

Markvardsen LK, Sindrup SH, Christiansen I, et al.

Journal of neuromuscular diseases 2023; (10(5)):787-796 doi:10.3233/JND-221615.

European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.

van Doorn PA, Van den Bergh PYK, Hadden RDM, et al.

European journal of neurology 2023; (30(12)):3646-3674 doi:10.1111/ene.16073.

Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.

De Lorenzo A, Liberatore G, Doneddu PE, et al.

European journal of neurology 2024; (31(4)):e16190 doi:10.1111/ene.16190.

Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials.

Latov N, Brannagan TH, Sander HW, Gondim FAA

Arquivos de neuro-psiquiatria 2024; (82(6)):1-7 doi:10.1055/s-0043-1777728.

[Cutting edge of diagnosis and treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) based on the EAN/PNS guideline 2021].

Kuwabara S

Rinsho shinkeigaku = Clinical neurology 2024; (64(5)):321-325 doi:10.5692/clinicalneurol.cn-001937.

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

Allen JA, Lin J, Basta I, et al.

The Lancet. Neurology 2024; (23(10)):1013-1024 doi:10.1016/S1474-4422(24)00309-0.

Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.

Klein CJ, Triplett JD, Murray DL, et al.

Neurology 2024; (103(11)):e210000 doi:10.1212/WNL.0000000000210000.

Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment.

Levine T, Muley S

Journal of the neurological sciences 2025; (468()):123313 doi:10.1016/j.jns.2024.123313.

Determinants of long-term disability in chronic inflammatory demyelinating polyradiculoneuropathy: A multicenter Korea/UK study of 144 patients.

Min YG, Jeon J, Kim SM, et al.

European journal of neurology 2025; (32(1)):e16575 doi:10.1111/ene.16575.

Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

Swart G, Skolka MP, Shelly S, et al.

Journal of the peripheral nervous system : JPNS 2025; (30(1)):e12682 doi:10.1111/jns.12682.

Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Koay S, Chen YC, Ransley G, et al.

Journal of the peripheral nervous system : JPNS 2025; (30(1)):e70007 doi:10.1111/jns.70007.

Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.

Tsoumanis P, Chatzoglou T, Smyris TI, et al.

Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.

A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy.

Caballero-Ávila M, Martin-Aguilar L, Collet-Vidiella R, et al.

Frontiers in immunology 2025; (16()):1575464 doi:10.3389/fimmu.2025.1575464.

Role of Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review.

Tozza S, Cassano E, Erra C, et al.

European journal of neurology 2025; (32(6)):e70226 doi:10.1111/ene.70226.

Minimal Clinically Important Difference for the Jamar Hand Grip Dynamometer in CIDP: A Korea-UK Study.

Min YG, Rajabally Z, Ju W, et al.

European journal of neurology 2025; (32(8)):e70335 doi:10.1111/ene.70335.

Nerve Conduction Abnormalities Beyond Conduction Block in Multifocal Motor Neuropathy. Impact on Diagnostic Criteria Accuracy.

Doneddu PE, Gallo C, Falzone Y, et al.

European journal of neurology 2025; (32(9)):e70300 doi:10.1111/ene.70300.

Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.

Tashiro T, Ogata H, Fukami Y, et al.

Neurology 2025; (105(9)):e214143 doi:10.1212/WNL.0000000000214143.

Autoimmune neuropathies: New guidelines and expert insights into clinical decision making.

van Doorn PA, Sommer C, Rajabally YA

Journal of the neurological sciences 2025; (479()):125659 doi:10.1016/j.jns.2025.125659.

Experiences of Immunoglobulin Therapy for Those with a Confirmed Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy: A Mixed-Methods Study with a Qualitative Patient Perspective Focus.

Hubsch A, Cashmore SJ, Mallick R, Gibbons B

Patient preference and adherence 2025; (19()):3999-4019 doi:10.2147/PPA.S543188.

Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis.

Ide T, Yoshikawa M, Suzuyama K, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; (33(2)):196-204 doi:10.1080/13506129.2026.2613126.

The journey to diagnosis for patients with CIDP: results from a real-world international survey.

Arvin-Berod C, Brackx F, Van de Veire L, et al.

Frontiers in neurology 2025; (16()):1748903 doi:10.3389/fneur.2025.1748903.

Embolic Ischemic Stroke Associated with Maintenance Intravenous Immunoglobulin Therapy.

Miyano R, Yoshida Y, Fujita K, et al.

Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.6976-25.

Efficacy and safety of anti-CD20 monoclonal antibody therapy for autoimmune nodopathies: a systematic review and meta-analysis.

Tao Z, Jiang Y, Gui Q, Ma J

Frontiers in neurology 2026; (17()):1759210 doi:10.3389/fneur.2026.1759210.

Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP.

Pang ZD, Sun H, Wei XJ, et al.

Frontiers in immunology 2026; (17()):1735745 doi:10.3389/fimmu.2026.1735745.

Post-COVID-19 chronic inflammatory demyelinating polyneuropathy: a case report of diagnosis and management.

Amro OW, Salah OE, Doudin AA, et al.

Annals of medicine and surgery (2012) 2026; (88(5)):2906-2910 doi:10.1097/MS9.0000000000004827.

Clinical features and treatment response of anti-Neurofascin 155 antibody-positive neuropathy in neurological Institute of Thailand.

Suanprasert N, Sinthuwong C, Apiwattanakul M, Hanchaiphiboolkul S

Journal of neuroimmunology 2026; (418()):578959 doi:10.1016/j.jneuroim.2026.578959.

Charcot-Marie-Tooth type 4 C misdiagnosed as CIDP: electrodiagnostic pitfalls and genetic confirmation.

Okhovat AA, Shahriyari H, Ghasemi A, et al.

Neurogenetics 2026; (27(1)).

The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

van Doorn IN, Baars AE, Wieske L, et al.

European journal of neurology 2026; (33(8)):e70726 doi:10.1111/ene.70726.